MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
2024年5月22日 - 8:30PM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant
natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases, today announced presentation of clinical
data on agenT-797 in a complex case of severe acute respiratory
distress (ARDS) at the American Thoracic Society (ATS) Annual
Meeting. These translational and mechanistic insights build on an
expanding dataset of clinical activity for patients with severe
ARDS.
“Consistent with our prior publication of the survival benefit
of agenT-797 in severe respiratory distress, the observed
improvement in this case further demonstrates the potential of
allogeneic iNKT cells in this setting,” said Dr. Terese Hammond,
University of California Los Angeles. “New therapeutic options,
like allogeneic cell therapies, are urgently needed to address the
critical unmet need in immune-compromised individuals with
respiratory distress. I believe this growing body of data
illuminates how iNKTs may have an impactful role in treating acute
critical illness and merits further investigation.”
Clinical Findings
- Patient: A
26-year-old chronically immunosuppressed patient post-renal
transplant contracted COVID-19 and progressed to severe hypoxemic
respiratory failure, requiring veno-venous extracorporeal membrane
oxygenation (VV-ECMO).
- Treatment: A single
dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day
13.
- Outcomes: Clinical
changes showed a rapid decrease in inflammatory cytokines,
including IL-18 following agenT-797 administration, consistent with
the data observed in the Phase 1 trial of agenT-797 in COVID-19
ARDS (Hammond, T.C., Nat Commun 2024). The patient was
extubated on day 37 and discharged home from the hospital on day
60, weaned off hemodialysis and returned to normal activities of
daily living (ADLs) within 6 months of dosing.
The full poster presentation can be found on the Publications
page of the MiNK website at
https://minktherapeutics.com/publications/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery, development, and commercialization of
allogeneic invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases. MiNK is advancing
a pipeline of both native and next generation engineered iNKT
programs, with a platform designed to facilitate scalable and
reproducible manufacturing for off-the-shelf delivery. The company
is headquartered in New York, NY. For more information, visit
https://minktherapeutics.com/ or @MiNK_iNKT. Information that may
be important to investors will be routinely posted on our website
and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the therapeutic and
curative potential of agenT-797 and iNKT cells the mechanism of
action, potency and safety, interim or top-line data, including
statements regarding clinical data of agenT-797, the anticipated
benefits of agenT-797 and clinical development plans and timelines.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These forward-looking statements are subject to risks and
uncertainties, including the factors described under the Risk
Factors section of the most recent Form 10-K filed with the SEC.
MiNK cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
MiNK undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 5 2024 まで 6 2024
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 6 2023 まで 6 2024